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SAMMANFATTNING 
Fibroblastlika tillväxtfaktorer är proteinhormoner som styr viktiga cellulära processer som till 
exempel proliferation, differentiering, migration, adhesion och överlevnad. Genom att binda 
till olika typer av membranbundna receptorer kan dessa peptider utöva olika effekter på 
målcellen. Vilka effekter de ger upphov till har olika förklaringsgrunder. Sålunda ger var och 
en av de 24 hittills kända FGF-varianterna delvis olika biologiska svar. Dessutom initierar 
olika receptorer (ffa FGF-R 1-4) olika intracellulära signalvägar som i sin tur ger upphov till 
olika biologiska sluteffekter. Receptorerna binder olika FGF–ligander med olika affinitet. 
Slutligen har olika målceller olika receptoruppsättningar vilket i sin tur påverkar det slutliga 
svaret. Således samspelar själva tillväxtfaktorerna med olika receptorer, med olika 
affinitetsegenskaper, som uttrycks i olika relativa tal på olika cellslag. Vilket biologiskt svar 
som utlöses beror på vilken kombination av fibroblastlik tillväxtfaktor, receptor och celltyp 
som samverkar.   
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ABSTRACT 
Fibroblast growth factors are signaling peptides that controls important cellular processes 
such as proliferation, differentiation, migration, adhesion and survival. Through binding to 
different types of receptors on the cell surface, these peptides can have different effect on the 
target cell. Which effect that is achieved depends on many factors. Thus, each of the 24 
known FGFs different biological responses. The FGF receptors (FGFR 1-4) initiates different 
intracellular pathways which in turn leads to different biological responses. The FGFs also 
binds different FGFs with different affinities. Finally, different types of cells express the 
FGFRs in different patterns and in altered extent which also affects the response. To 
summarize it, the response from a FGF depends on the combination of FGF, receptor and the 
type of cell that collaborate. 
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INTRODUCTION 
The fibroblast growth factors (FGFs) are members of a large family consisting of 24 
polypeptides. (Engström & Granerus, 2006). These molecules have been studied for many 
years but their functions are not yet fully understood. The first fibroblast growth factors were 
isolated from bovine brain tissue in 1977 (Gospodarowicz et al., 1978), and since then 
scientists have worked hard to understand the effects of these peptides as each member elicits 
different biological responses in different cells (Granerus & Engström, 2000). It has been shown 
that the fibroblast growth factors are involved in processes including cell proliferation, cell 
migration, differentiation, adhesion and survival. The targets of the FGFs are mainly two 
classes of receptors; the tyrosine kinase receptor family and the co-receptors heparin sulfate 
proteoglycans. The growth factor – receptor interaction is not a straight forward process. 
Different FGFs have different affinities for different receptors. Moreover, activation of 
multiple receptors affects which action that will follow. In other words, a full understanding 
of growth factor – receptor interaction will help understand how a specific biological response 
is achieved. The different FGFs have different affinities for these receptors which will lead to 
different effects on the cell.  
 
The reason for trying to fully understand these growth factors, their receptors and the effects 
they lead to, is that scientists have reasons to believe that they play an important role in tumor 
development and angiogenesis, and that further understanding of the growth factors exact role 
may lead to a further step in combatting cancer. 
 
The purpose of this review is to describe the different members of the fibroblast growth factor 
family, their receptors and how the interactions between the growth factor and the receptors 
can lead to various cellular responses.  
 
MATERIAL AND METHODS 
To find the literature needed to write this review, databases such as Web Of Knowledge and 
PubMed were used. While searching for relevant articles I used keywords such as “Fibroblast 
growth factors”, “effects on proliferation and migration”, “fibroblast growth factors and their 
receptors”, “FGF-1” and so on. Some of the articles were hard to find, while many of them is 
available online. A couple of articles were kindly provided by the supervisor.  
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LITTERATURE REVIEW 
 
The fibroblast growth factors 
Fibroblast growth factors are secreted polypeptide ligands that bind to different receptors that 
are located on the cell surface of target cells in a variety off tissues. The structure of the FGFs 
has been revealed through high-resolution X-ray diffraction as well as with, nuclear magnetic 
resonance, NMR (Arunkumar et al., 2002) and shows that the FGF archetype consists of 12 
strands, which are linked together forming a three-fold symmetrical structure of beta sheets 
(Zhu et al., 1991). All 23 members of the FGF family have the same core of around 140 
amino acids. Twenty two of the FGFs have been recognized in humans while FGF-24 has 
only been identified in zebrafish embryos (Fischer et al., 2003). FGF-15 occurs in mice and it 
is closely related to human FGF-19 (Nishimura et al., 1999). 
 
The first FGFs ever to be found was the FGF 1 and FGF 2, also called the acidic and basic 
fibroblast growth factors (Fitzgerald et al., 2001). They were found to have a significant effect 
on cell migration, proliferation, differention and angiogenesis. Another name often used for 
the fibroblast growth factors are heparin binding growth factors, since they all have  high 
affinity for heparan sulfate. Binding of fibroblast growth factors to different 
glucosaminoglycans, such as heparan sulfate, makes FGFs resistant to degradation and so 
FGFs can exist in the extracellular matrix as a reservoir. Some of the fibroblast growth factors 
also play an important role in embryogenesis, organ development and wound healing, which 
makes them an interesting object for research.  
 
The FGFs are often divided into subgroups (Beenken & Moosa, 2009). The members of each 
family have similar qualities. Firstly, the FGF11-FGF14 aren’t always included in the FGF-
family because unlike the other FGFs they do not have the ability to bind to and activate FGF-
receptors. Instead, they are called homologous factors, because their genomic structure highly 
resembles the FGFs. FGF1 and FGF2, also called the acidic and basic FGFs are members of 
the FGF1 subfamily. They were the first FGFs to be discovered but despite that, their 
physiological roles are still unclear. It is likely that they affect the vascular tone and lowers 
bloodpressure (Cuevas et. al., 1991). However, it is known that FGF2 have angiogenic 
properties and promotes proliferation and migration and inhibits apoptosis of endothelial cells 
(Zhou at al., 1998). The FGF4 subfamily contains FGF4 and FGF5. FGF4 is particularly 
important during organ development. It affects processes like trophoblast proliferation as well 
as limb and heart valve development while FGF5 is an important factor in the hair growth 
cycle regulation (Pethö-Schramm et al., 1996). FGF3, FGF7 and FGF10 and FGF22 are 
members of the FGF7 subfamily. FGF3 plays and important part in development of the inner 
ear structure while FGF7 is an important factor in kidney development and it is sometimes 
refered to as keratinocyte growth factor (KGF).  FGF22, FGF7 and FGF10 are presynaptic 
organisers involved in vesicle clustering and neurite branching (Umemori et al., 2004). 
Another subfamily contains FGF8, FGF, 17 and FGF18. FGF8 is an important factor in limb, 
ear, eye and brain development and together with FGF17, FGF8 also have an effect on the 
development of the forebrain (Bernhard et al., 2003). FGF18 is required for correct 
development of bone tissue. The FGF9 subfamily consists of FGF9, FGF16 and FGF20. 
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FGF9 up regulates proliferation of mesenchymal tissue which initiates secretion of ligands 
from the FGF3, FGF7, FGF10 and FGF22 subgroups. Accordingly, knockout of the FGF9 
leads to reduced production of different ligands and reduced mesenchymal-epithelial 
signaling (Colvin et al., 2001).  
 
FGF19, FGF21 and FGF23 belong to a subfamily called the endocrine FGF ligands (Wu et 
al., 2011). One of the properties that distinguish them from the other FGFs is the fact that they 
need the presence of two types of klotho-proteins to form the FGF – receptor complex in the 
tissue. This is a consequence of their low affinity toward heparin sulfate proteoglycan. The 
two types of klotho proteins (αKlotho and βKlotho) are selectively used as co-receptors by the 
FGF19 subfamily members (Wu, 2012). FGF19 stimulates bile acid synthesis and initiates 
oxidation of fatty acids. FGF21 gives a fasting response, by stimulating glucose uptake in 
adipocytes and so, reducing the levels of glucose in the bloodstream. Injections of FGF21 in 
diabetic and obese mice lead to reduced concentration of insulin, glucagon, glucose and 
triglycerides in the blood. Continues injections of FGF21 in obese mice reduced the body 
weight by 20%. Finally FGF23 is an important vitamin D regulator.  
 
 
The FGF receptors 
The FGFs binds to two different classes of receptors and it is important to state that many 
different ligands can activate the same receptor. FGFs bind simultaneously to low-affinity, 
heparin sulfate proteoglycans and high-affinity FGF-receptors. The high affinity receptors 
consist of one extracellular part that contains between one and three Ig-SF ( domains, one 
transmembrane domain and one intracellular tyrosine kinase domain. The high-affinity 
receptors have one unique part that distinguishes it from other receptors. That is an “acid box” 
that consists of eight acidic residues located between the first and second Ig-SF domains. The 
first Ig-SF domain and the acid box probably contribute to autoinhibition while domains 2 and 
3 are FGF ligand binding sites (Wesche et al,. 2011). 
 
Four FGF-receptors have been identified to date, but it is believed that there are others 
hitherto undiscovered. The common name for these receptors is FGFR 1-4 and they are coded 
for by separate genes. Differential splicing gives rise to multiple alternative forms of the 
receptors. For example splicing of the gene that codes for the Ig like domain 3 causes variants 
with different specificities of the binding site. The different isoforms of the receptors are 
expressed in different organs, for instance, the FGFR3IIIb is mainly located in epithelial 
tissues and the IIIc forms are mainly expressed in tissues of mesenchymal origin. Both 
isoforms have separate ligands which only bind to the specific receptor. This means that 
mesenchymal cells produce ligands that only activate IIIc receptor in order to achieve a 
paracrine signal.  
 
The FGF-receptors are unevenly distributed in several tissues in the body, and the patterns in 
which they occur is specific to each tissue. Studies have shown that FGFR-1 is expressed in 
the skin, calvarial bones, growth plates and in high amounts in the fetal brain. FGFR-2 also 
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exists in the brain, growth plates and calvarial bone, but also in the liver, lungs, intestine and 
kidneys. The FGFR-3 is also expressed in the brain, growth plates and calvarial bone as well 
as in the lung, kidney and intestines. FGFR-4 can be found in lungs, kidney, liver, pancreas, 
intestine, fetal adrenals, spleen and striated muscle (Fitzgerald et. al. 2001). 
 
The low affinity receptors are present on the surface of most cells. They are so called heparan 
sulfate proteoglycans, HSPGs for short. They have a much simpler structure then the high 
affinity receptors with their single proteoglycan core that can bind to 2 or 3 negatively 
charged heparan sulfate chains. The binding site for the FGF ligands is the polysaccharides 
(heparan sulfate chains). The HSPGs has two different very important functions. The first is 
that binding of the FGF to the HSPGs protect the growth factors from from degradation and 
so it can act as a extracellular buffert. HSPGs are also involved in the complex formation 
between the FGFs and the FGFR. Binding of the FGFs to their respective receptors induces 
dimerisation and formation of a ternary complex containing FGF, FGFR and heparan sulfate. 
 
 
FGF signaling 
A signal through activation of the FGFR requires a dimerisation, a prerequisite for moving the 
intracellular kinases closer to each other which initiates the onset of different intracellular 
signaling pathways that leads to adjustment of gene expression (Schlessinger, 2010). 
Formation of the receptor dimers activates their intracellular tyrosine kinases which allow 
them to transphosphorylate the tyrosine residues on both dimers of the receptor. These 
residues can act as a binding site for signaling molecules containing src homology-2 (SH2) or 
phosphotyrosine binding (PTB) domains. The signaling molecules are often bound to 
different docking proteins. There are a few known signal transduction pathways and some of 
them are better understood then others. The RAS-MAP kinase pathway is one of the most 
studied signaling pathways. It involves the docking protein FRS2α which becomes activated 
by the tyrosine residues on the activated FGF receptor. FRS2α is the core of a complex 
formed by the adaptor Grb2, tyrosine phosphatase Shp2 and the docking protein GAB1. To 
Grb2 binds the guanine nucleotide exchange factor SOS, which in turn activates the Ras-MAP 
kinas. The MAP kinases are regulatory proteins that affect different kinases and transcription 
factors and thereby regulating target genes. The effects gained by stimulating the Ras-Map 
kinase pathway are mainly mitogenic (Wesche et al., 2011). 
 
GAB1 also leads to activation of another important pathway through activation of PI-3 kinase. 
P-I-3 activates PDK which in turn activates ATK/PKB. The effects of ATK are anti-apoptotic. 
The activated FGF receptor can also lead to hydrolysis of Pt Ins and activation of PDK and 
ATK. FGFs can also act on intracellular calcium levels through recruitment of the SH2 
domain of PLCγ to the receptor. Activation of PLCγ allows it to hydrolyze Pt Ins P2 which 
leads to formation of diaglycerol (DAG) and Ins P3. The effect of DAG and Ins P3 is release 
of calcium and activation of calcium-dependent protein kinases which affects cytoskeletal 
organization (Schlessinger, 2000). 
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Diversity in cellular responses 
The effects achieved by these signaling cascades are not always the same on all cells. The 
MAPK pathway is always seen as a response to FGF ligand binding while others, such as 
AKT activation, differs between cell types. Studies have shown that activation of MAPK 
leads to proliferation of oligodendrocyte precursors and endothelial cells. Inhibition of PLCγ 
on the other hand, did not affect the oligodendrocytes (Dailey et al., 2005). Ligand activation 
of the MAPK pathway has been shown to stimulate proliferation in fibroblasts. Studies 
performed on chondrocytes showed that MAPK activation, unlike PLCγ and PI-3, leads to 
interruption of the cell cycle.  
 
Another explanation to the variety between cell responses is the fact that the intracellular 
signaling pathways are influenced by a number of regulators. A few example of these are the 
Sproty proteins, MAPK phosphatase 3 and SEF which are inhibitory molecules that either 
bind to different molecules (Sproty protein) and inhibits them or act as regulatory feedback 
(SEF – has similar expression to FGF). There are also excitatory molecules which up regulate 
the signaling pathways such as some FLRT, a family of transmembrane proteins (Beenken et 
al., 2009).  
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It is known that the FGFs have different effects on different tissues depending on the 
developmental stage of the organ and the concentration of growth factor present there. The 
effects of FGF2 on the development of oligodendrocytes have been studied and it has been 
found that FGF2 induces different, stage-specific responses in the cells (Fortin et al., 2005). An 
experiment on oligodendrocytes showed that FGF-2 induced proliferation in the cells while 
FGF-8,9 and 17 had no effect no matter how high the concentration was or how long the 
duration was. The reason to this difference in response is the fact that FGF-2 rapidly activates 
the MAPK pathway while FGF-8,9 and 17 had a much weaker and slower effect on the 
MAPK pathway. The effects of FGF-2 on differentiation have also been closely studied 
(Fortin et al., 2005) and the conclusion was that FGF-2 inhibits the differentiation of 
oligodendrocyte progenitors. However, further studies showed that FGF-9, unlike FGF-2, did 
not block the differentiation of the oligodendrocytes.  
 
The effects of FGFs on mature oligodendrocytes were also examined: FGF-2 induces multiple 
responses in the mature cell line such as elongation, inhibition of myelin protein synthesis and 
reentering into the cellcycle. These effects where studied after of FGF-8,9, 17 and 18 addition 
and it was shown that only FGF-2 had any effect on the cell-cycle. FGF-9 and 18 gave the 
same results as FGF-2 on differentiation of the oligodendrocytes but treatment with FGF-9 
and 18 did not result in loss of myelin-like membranes which was observed in FGF-2 treated 
cells. FGF-8 and FGF-17 did not increase cell size, which suggests that these cells can 
distinguish between different FGFs. 
 
The expression patterns of the receptors may also play a certain part in the response of FGF 
signaling. It has been confirmed that cells express different FGFRs during different 
developmental phases. The patterns in which the FGFRs occurs changes as the cells 
differentiate. An example is the FGFR expression in oligodendrocytes during their 
differentiation where FGFR1 are expressed throughout the development while FGFR2 was 
more prominent during terminal differentiation and FGFR3 was downregulated at the end of 
oligodendrocyte differentiation.  
 
It is also possible that different FGF-FGFR interactions lead to different responses. This 
theory was tested by adding FGFR inhibitors to oligodendrocytes during different phases of 
development. The result was that during progenitor phase, only activation of FGFR1 (by 
FGF-2) induced proliferation while inhibition of proliferation requires FGF-8, FGF-17 or 
FGF-18 bound to FGFR-3. The same experiment was performed on differentiated 
oligodendrocytes and it showed that activation of FGFR1 is required for cells to re-enter cell 
cycle and not FGFR3. The cell elongation requires activation of FGFR2 by FGF-2, FGF-9 
and FGF-18.  
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It is also known that the responses from FGFs are concentration dependent, which adds yet 
another factor to determine the response. A study on lens epithelial cells showed that low 
concentrations (150pg/ml) of FGF-1 and FGF-2 initiated proliferation. As higher 
concentrations (3ng/ml) of FGF were added, the cells started to migrate. To achieve cell 
differentiation, an even higher concentration (40ng/ml) of FGFs was required (McAvoy & C 
Chamberlain, 1989). It also seems like the time interval in which the cells are exposed to the 
FGFs matters. Proliferation and migration of the cells were achieved within 24 h while 
differentiation of the cells was seen after 4 days. It was also shown that proliferation and 
migration can occur simultaneously and higher concentration leads to a more pronounced 
response.    
 
DISCUSSION 
Fibroblast growth factors play a pivotal role in the regulation of key developmental processes.  
There is mounting evidence for the importance of correct spatial and temporal regulation of 
the expression of FGF:s  and their receptors. Deregulation of this signaling system can lead to 
a variety of developmental aberrations as e.g. skeletal disorders and cancer (Dailey et al., 
2005).  
 
This review has highlighted the differential effects of the 24 hitherto discovered members of 
the FGF family. These ligands interact with a family of tyrosine kinase receptors that can 
elicit a variety of biological responses. We conclude that different FGFs do not necessarily 
have the same effect on one type of cell, because the 24 FGFs exert different cellular 
responses. Moreover, different intracellular pathways are activated to a different extent 
depending on which ligand that initiates the activation.  
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One particular type of FGF can also give rise to different responses at different stages of 
development. The picture is further complicated by different cellular expression of the 
tyrosine kinase receptors during different phases of development. Finally, the response to 
FGF activation may depend on the availability of substrates and other intracellular regulators. 
A key question is then to understand how these different responses are generated and more 
specifically how very similar elicitations can lead to differences in secondary patterns of gene 
expression which directs the intracellular signal transduction to generate a particular cellular 
response. 
 
Vast genetic data on mammalian development has pointed at the importance of a finely 
orchestrated role for the FGF family for normal development. The FGF;s are part of an 
extended gene family  including TGFBeta/BMP;s, Hedgehog, Notch and Wnt (Goldfarb, 
1996). Albeit structurally different, they all combine their efforts to steer undifferentiated 
cells towards lineage determination, proliferation, locomotion and differentiation. 
 
This concept also suggests that there is a role for cross talk between the activation of FGF-
receptors and other signaling pathways. There is mounting evidence that FGF-activation may 
activate or repress other signaling pathways as e.g. TGFBeta/BMP, IGF, IHH/PTHIH and 
Notch (Dailey et al 2005).  However the best characterized developmental crosstalk is that 
between FGF and Wnt. In such distinct areas as trachea development in Drosophila, 
mesoderm induction in Xenopus, and CNS, kidney and tooth development in lower mammals 
(Moon et al., 1995) cross talk between FGFs and Wnt can lead to convergence or divergence 
of the signal routes activated by each pathway. Moreover it has been suggested that activation 
of one signal can confer competence on the other.  
 
This signaling system must be tightly regulated to avoid dysregulation of development. Even 
minor mutations or changes in gene activation can lead to tissue damage or even malignant 
disease. 
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